INDUCTION OF PROTECTIVE CYTOTOXIC T-CELL RESPONSES IN THE PRESENCE OFHIGH TITERS OF VIRUS-NEUTRALIZING ANTIBODIES - IMPLICATIONS FOR PASSIVE AND ACTIVE IMMUNIZATION
P. Seiler et al., INDUCTION OF PROTECTIVE CYTOTOXIC T-CELL RESPONSES IN THE PRESENCE OFHIGH TITERS OF VIRUS-NEUTRALIZING ANTIBODIES - IMPLICATIONS FOR PASSIVE AND ACTIVE IMMUNIZATION, The Journal of experimental medicine, 187(4), 1998, pp. 649-654
The effect of preexistent virus-neutralizing antibodies on the active
induction of antiviral T cell responses was studied in two model infec
tions in mice. Against the noncytopathic lymphocytic choriomeningitis
virus (LCMV), pretreatment with neutralizing antibodies conferred imme
diate protection against systemic virus spread and controlled the viru
s below detectable levels. However, presence of protective antibody se
rum titers did not impair induction of antiviral cytotoxic T lymphocyt
e (CTL) responses after infection with 10(2) PFU of LCMV. These CTLs e
fficiently protected mice independent of antibodies against challenge
with LCMV-glycoprotein recombinant vaccinia virus; they also protected
against otherwise lethal lymphocytic choriomeningitis caused by intra
cerebral challenge with LCMV-WE, whereas transfused antibodies alone d
id not protect, and in some cases even enhanced, lethal lymphocytic ch
oriomeningitis. Against the cytopathic vesicular-stomatitis virus (VSV
), specific CTLs and Th cells were induced in the presence of high tit
ers of VSV-neutralizing antibodies after infection with 10(6) PFU of V
SV, but not at lower virus doses. Taken together, preexistent protecti
ve antibody titers controlled infection but did not impair induction o
f protective T cell immunity. This is particularly relevant for noncyt
opathic virus infections since both virus-neutralizing antibodies and
CTLs are essential for continuous virus control. Therefore, to vaccina
te against such viruses parallel or sequential passive and active immu
nization may be a suitable vaccination strategy to combine advantages
of both virus-neutralizing antibodies and CTLs.